Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 2/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3117545 | 0.86 | EGFR (0.49) | EGFRLMNABTKRIPK2ACVR1 | |
| SCHEMBL28953972 | 0.73 | EGFR (0.47) | EGFRBTKGLA | |
| SCHEMBL3123936 | 0.73 | SRC (0.47) | EGFRBTKAURKB | |
| SCHEMBL1382429 | 0.69 | EGFR (0.54) | EGFR | |
| SCHEMBL13193469 | 0.69 | CSF1R (0.64) | — | |
| SCHEMBL21044835 | 0.69 | BTK (0.73) | EGFRBTK | |
| SCHEMBL20533284 | 0.68 | EGFR (0.52) | EGFRPKMLMNABTKFFAR2 | |
| SCHEMBL3123123 | 0.67 | EGFR (0.47) | EGFRBTK | |
| SCHEMBL28954058 | 0.67 | BTK (0.58) | BTK | |
| SCHEMBL18553766 | 0.65 | HTR6 (1.00) | HTR6PKMHPGDLMNAKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225098-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-12-04 | — | — | US | claimed |
| US-20030199525-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-23 | — | — | US | claimed |
| US-7829570-B2 | Substituted 4-amino isoxazolo[5,4-d]pyrimidines as kinase inhibitors | ABBOTT LABORATORIES (US) | 2010-11-09 | — | — | US | disclosed |
| US-20100041676-A1 | Kinase inhibitors | ABBVIE INC. | 2010-02-18 | — | — | US | disclosed |
| US-20030225098-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-12-04 | — | — | US | disclosed |
| US-20030199525-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199525-A1 | Kinase inhibitors | MAP3K19, MAP3K9, MAP3K1 | HTR6 3350/4885EGFR 346/4885NPY5R 4661/4885 |
| US-20030225098-A1 | Kinase inhibitors | MAP3K19, MAP3K9, MAP3K1 | HTR6 2848/4885EGFR 298/4885NPY5R 4381/4885 |
| US-20100041676-A1 | Kinase inhibitors | MAP3K19, MAP3K20, MAP3K6 | HTR6 4079/4885EGFR 232/4885NPY5R 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.